United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund Lowers Stock Position in Zoetis Inc. $ZTS

United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund trimmed its position in shares of Zoetis Inc. (NYSE:ZTS) by 95.6% in the second quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 11,600 shares of the company’s stock after selling 251,749 shares during the period. United Super Pty Ltd in its capacity as Trustee for the Construction & Building Unions Superannuation Fund’s holdings in Zoetis were worth $834,000 as of its most recent SEC filing.

Several other large investors have also made changes to their positions in the company. Vanguard Group Inc. increased its stake in Zoetis by 12.9% during the fourth quarter. Vanguard Group Inc. now owns 47,780,974 shares of the company’s stock worth $6,011,802,000 after acquiring an additional 5,474,210 shares during the last quarter. J. Stern & Co. LLP lifted its stake in shares of Zoetis by 12,431.2% in the 4th quarter. J. Stern & Co. LLP now owns 24,069,492 shares of the company’s stock valued at $3,028,423,000 after purchasing an additional 23,877,416 shares in the last quarter. State Street Corp lifted its stake in shares of Zoetis by 0.8% in the 4th quarter. State Street Corp now owns 19,796,891 shares of the company’s stock valued at $2,490,845,000 after purchasing an additional 149,382 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Zoetis by 1.7% during the 4th quarter. Geode Capital Management LLC now owns 11,327,679 shares of the company’s stock worth $1,420,294,000 after purchasing an additional 189,235 shares during the period. Finally, Norges Bank purchased a new stake in shares of Zoetis during the 4th quarter worth about $734,425,000. 92.80% of the stock is owned by hedge funds and other institutional investors.

Zoetis Stock Performance

Shares of NYSE:ZTS opened at $73.64 on Friday. The business’s 50-day simple moving average is $76.30 and its 200 day simple moving average is $99.01. The company has a market cap of $30.43 billion, a P/E ratio of 12.13, a PEG ratio of 1.28 and a beta of 0.74. The company has a debt-to-equity ratio of 2.87, a quick ratio of 1.84 and a current ratio of 3.08. Zoetis Inc. has a one year low of $71.45 and a one year high of $160.48.

Zoetis (NYSE:ZTS) last released its quarterly earnings results on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. During the same quarter in the prior year, the business earned $1.76 EPS. Zoetis’s quarterly revenue was down .2% compared to the same quarter last year. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. On average, sell-side analysts forecast that Zoetis Inc. will post 6.19 earnings per share for the current fiscal year.

Zoetis Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Stockholders of record on Monday, July 20th will be paid a $0.53 dividend. The ex-dividend date is Monday, July 20th. This represents a $2.12 annualized dividend and a dividend yield of 2.9%. Zoetis’s dividend payout ratio is 34.93%.

Analyst Ratings Changes

Several research analysts recently commented on the stock. Zacks Research lowered shares of Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th. Stifel Nicolaus decreased their price objective on shares of Zoetis from $95.00 to $85.00 and set a “hold” rating for the company in a research note on Friday, June 26th. Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research report on Friday, August 7th. Wall Street Zen downgraded shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. Finally, HSBC reduced their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a report on Monday, July 6th. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. Based on data from MarketBeat, Zoetis currently has a consensus rating of “Hold” and an average price target of $109.62.

Zoetis Company Profile

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.